New pill shows promise for chinese psoriasis patients
NCT ID NCT06122649
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study tested a daily pill called apremilast in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either the drug or a placebo for 16 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75%. This is a disease control study, meaning the treatment manages symptoms but does not cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Changshu No2 Peoples Hospital
Suzhou, Jiangsu, 215006, China
-
Chengdu Second Peoples Hospital
Chengdu, Sichuan, 610017, China
-
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, 330000, China
-
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, 510091, China
-
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750003, China
-
Nanyang First Peoples Hospital
Nanyang, Henan, 473002, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Peoples Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, 830001, China
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shandong Provincial Hospital For Skin Diseases,Shandong First Medical University
Jinan, Shandong, 830001, China
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200443, China
-
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350000, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Sichuan, 400010, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
Wuxi Peoples Hospital
Wuxi, Jiangsu, 241023, China
-
Yichang Central Peoples Hospital
Yichang, Hubei, 443003, China
Conditions
Explore the condition pages connected to this study.